Open an account

Acusphere

ACUS · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About ACUS

Acusphere, Inc. is a pharmaceutical company, which engages in the development of drugs and formulations of existing drugs using proprietary micro particle technology. The company is headquartered in Lexington, Massachusetts. The company went IPO on 2003-10-08. The firm is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The firm's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The firm has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).

Employees
0
Headquarters
Lexington, Massachusetts
Listed
Oct 8, 2003
Sector
Health Care
Industry
Pharmaceuticals
Website
acusphere.com

ACUS key statistics

Market cap
495
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
370
Volume
100
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0001
52 Week low
$0.00

Acusphere (ACUS) at a glance

As of Jan 27, 2026, Acusphere (ACUS) shares are priced at $0.00, giving the company a market cap of 495 and a price-to-earnings ratio of 0.00.

Volume so far is 100 shares, below the average of 370 shares a day.

Over the past year Acusphere has ranged from $0.00 to $0.0001, and now sits 0% of the way up that range.

Acusphere met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q4 FY08 it reported -$6.70 per share against an estimate of -$2.14.

ACUS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 5.3% on average.

  1. Q1 FY07: reported -$3.40 per share against an estimate of -$3.20
  2. Q2 FY07: reported -$3.80 per share against an estimate of -$3.26
  3. Q3 FY07: reported -$3.20 per share against an estimate of -$2.91
  4. Q4 FY07: reported -$2.70 per share against an estimate of -$2.96
  5. Q1 FY08: reported -$3.00 per share against an estimate of -$2.45
  6. Q2 FY08: reported -$2.50 per share against an estimate of -$2.55
  7. Q3 FY08: reported -$2.30 per share against an estimate of -$2.04
  8. Q4 FY08: reported -$6.70 per share against an estimate of -$2.14

Similar companies

Companies in the same industry as Acusphere

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.